Ultragenyx Pharmaceutical Inc. (RARE)
收市後：
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,276
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1.46M | 1.27M | 1960 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 184.81k | 無 | 1978 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 846.74k | 無 | 1978 |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 860.05k | 無 | 1966 |
| Mr. Erik Harris | Executive VP & Chief Commercial Officer | 878.77k | 無 | 1971 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 無 | 無 | 1971 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | 無 | 無 | 1965 |
| Mr. Thomas R. Kassberg | Chief Business Officer & Executive VP | 714.84k | 無 | 1960 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 無 | 無 | 1965 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and EVP of Gene Therapy Research & Development | 331.33k | 無 | 1965 |
描述
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
公司管治
截至 2024年5月1日 止，Ultragenyx Pharmaceutical Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：2；董事會：2；股東權利：7；現金賠償：5。
